

Vincent M Crowley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5658652/publications.pdf>

Version: 2024-02-01

18
papers

1,082
citations

567144
15
h-index

839398
18
g-index

20
all docs

20
docs citations

20
times ranked

1137
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemical proteomic identification of functional cysteines with atypical electrophile reactivities. <i>Tetrahedron Letters</i> , 2021, 67, 152861.	0.7	6
2	DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras. <i>Journal of the American Chemical Society</i> , 2021, 143, 5141-5149.	6.6	86
3	Functionalized Scout Fragments for Site-Specific Covalent Ligand Discovery and Optimization. <i>ACS Central Science</i> , 2021, 7, 613-623.	5.3	27
4	A proteome-wide atlas of lysine-reactive chemistry. <i>Nature Chemistry</i> , 2021, 13, 1081-1092.	6.6	107
5	An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells. <i>Cell</i> , 2020, 182, 1009-1026.e29.	13.5	194
6	Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16. <i>Nature Chemical Biology</i> , 2019, 15, 737-746.	3.9	282
7	The Proteome-Wide Potential for Reversible Covalency at Cysteine. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 11385-11389.	7.2	36
8	The Proteome-Wide Potential for Reversible Covalency at Cysteine. <i>Angewandte Chemie</i> , 2019, 131, 11507-11511.	1.6	7
9	Trifunctional High-Throughput Screen Identifies Promising Scaffold To Inhibit Grp94 and Treat Myocilin-Associated Glaucoma. <i>ACS Chemical Biology</i> , 2018, 13, 933-941.	1.6	17
10	Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2793-2805.	2.9	28
11	Second Generation Grp94-Selective Inhibitors Provide Opportunities for the Inhibition of Metastatic Cancer. <i>Chemistry - A European Journal</i> , 2017, 23, 15775-15782.	1.7	29
12	Resorcinol-Based Grp94-Selective Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1013-1018.	1.3	28
13	Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma. <i>Scientific Reports</i> , 2017, 7, 17951.	1.6	28
14	Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3471-3488.	2.9	54
15	Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?. <i>Medicinal Research Reviews</i> , 2016, 36, 92-118.	5.0	86
16	An Efficient Synthesis of 4(5)-Benzyl-L-histidines Employing Catalytic Transfer Hydrogenolysis at Elevated Temperatures. <i>Synthesis</i> , 2014, 46, 515-521.	1.2	4
17	Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma. <i>Human Molecular Genetics</i> , 2014, 23, 6470-6480.	1.4	38
18	Development of radamide analogs as Grp94 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4083-4098.	1.4	25